logo

NEUROCRINE(NSDQ:NBIX)
Neurocrine Biosciences is a neuroscience-based company focused on the discovery and development of novel therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases and disorders. The company''s neuroscience, endocrine and immunology disciplines provide a unique biological understanding of the molecular interaction between central nervous, immune and endocrine systems for the development of therapeutic interventions for anxiety, depression, insomnia, stroke, malignant brain tumors, multiple sclerosis, obesity and diabetes.
# Employees: 125
Address: 12790 El Camino Real,San Diego,CA,USA
Phone: 858 617-7600
Fax: 858 658-7601
Website: www.neurocrine.com
Email: ir@neurocrine.com
Sector: Medical
Industry: MED-DRUGS
Executive Officers
Joseph A. Mollica (Chmn.)
Gary A. Lyons (Presi.; C.E.O.; Dir.)
Paul W. Hawran (Exec. V.P.; C.F.O.)
Thomas W. Mitchell (Dir.)
Richard F. Pops (Dir.,)
Dividend
Ex-Dividend Date: N/A
Annual Dividend: N/A
Current Dividend Yield: N/A
Dividend Paid (3 months): N/A
Indicated Dividend: N/A
Earnings
Last Earnings Date: 9/30/2009
Next Earnings Date(Expected): 2/9/2010
Mean EPS (Next Qtr): ($0.30)
Mean EPS (Year): ($1.43)
Mean Estimate(Long Term): ($0.01)
P/E Ratio(Based on EPS estimate): -0.010
Number of Estimates: 6
Shares Performance
Period NBIX Compare to S&P
YTD -34.06 % -45.43 %
4 Weeks -4.95 % -9.77 %
12 Weeks -31.05 % -35.79 %
Shares Information
Analyst Coverage: Y
Avg Volume: 159825
Shares Outstanding: 39M
Market Cap: $0.08B
52 Week High: $4.09
52 Week Low: $2.00
P/E Ratio: -0.010
PEG Ratio: -0.010
Split: On 1/1/1990 NBIX split by factor of 1.150
Earnings Performance
EPS Growth in Last Quarter: 43.24 %
EPS Growth in Last Year: 54.35 %
Sales Growth in Last Quarter: 0.00 %
Sales Growth in Last Quarter: -3.68 %
Financials
Qtr Book Value: $77.08
Cash Flow/Share: ($0.01)
Change in Payout Ratio: -0.010
Price/Sales: 28.040
Fundamental data is provided by Zacks Investment Research, market data is provided by AlphaTrade. , and Commentary and Press Releases provided by Quotemedia